Cargando…

Identifying challenges in neurofibromatosis: a modified Delphi procedure

Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) are rare conditions with pronounced variability of clinical expression. We aimed to reach consensus on the most important manifestations meriting the development of drug trials. The five-staged modified Delphi p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhaenens, Britt A. E., Ferner, Rosalie E., Bakker, Annette, Nievo, Marco, Evans, D. Gareth, Wolkenstein, Pierre, Potratz, Cornelia, Plotkin, Scott R., Heimann, Guenter, Legius, Eric, Oostenbrink, Rianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071842/ https://www.ncbi.nlm.nih.gov/pubmed/33903738 http://dx.doi.org/10.1038/s41431-021-00892-z

Ejemplares similares

ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1
por: Carton, Charlotte, et al.
Publicado: (2023)

Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future
por: Reilly, Karlyne M., et al.
Publicado: (2017)

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
por: Legius, Eric, et al.
Publicado: (2021)

Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1
por: Ottenhoff, Myrthe J., et al.
Publicado: (2020)

Reliability of functional outcome measures in adults with neurofibromatosis 1
por: Mullin, Rebecca L, et al.
Publicado: (2018)

Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2
por: Ferner, Rosalie E., et al.
Publicado: (2014)

Legius Syndrome and its Relationship with Neurofibromatosis Type 1
por: DENAYER, Ellen, et al.
Publicado: (2020)

Neurofibromatosis I and multiple sclerosis
por: Bergqvist, Christina, et al.
Publicado: (2020)

Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas
por: Byrne, Susan, et al.
Publicado: (2017)

Mediastinal mass in an tuberculosis-exposed 2-year old child with neurofibromatosis type 1 – TB or not TB?
por: Krüger, Renate, et al.
Publicado: (2020)

Hemostasis and Type 1 Neurofibromatosis
por: Niddam, Jeremy, et al.
Publicado: (2017)

Lymphoproliferative malignancies in patients with neurofibromatosis 1
por: Bergqvist, Christina, et al.
Publicado: (2021)

ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis
por: Evans, D. Gareth, et al.
Publicado: (2022)

The effect of post-injection (18)F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1
por: Lovat, Eitan, et al.
Publicado: (2017)

Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
por: Cook, Gary J. R., et al.
Publicado: (2017)

Motor problems in children with neurofibromatosis type 1
por: Rietman, André B., et al.
Publicado: (2017)

Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire
por: Ferner, Rosalie E, et al.
Publicado: (2017)

Worries and needs of adults and parents of adults with neurofibromatosis type 1
por: Rietman, Andre B., et al.
Publicado: (2018)

Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
por: Merker, Vanessa L., et al.
Publicado: (2022)

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
por: Banerjee, Jineta, et al.
Publicado: (2023)

Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1
por: Cassiman, Catherine, et al.
Publicado: (2017)

Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient‐CEntric ClinicAl TRial PLatforms
por: Dhaenens, Britt A. E., et al.
Publicado: (2023)

Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
por: Bergqvist, Christina, et al.
Publicado: (2020)

Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool
por: Armand, Marie-Laure, et al.
Publicado: (2019)

Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
por: Evans, D. Gareth R., et al.
Publicado: (2019)

Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study
por: Carlier, A., et al.
Publicado: (2016)

Correction: Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
por: Evans, D. Gareth R., et al.
Publicado: (2019)

KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
por: Valensin, Silvia, et al.
Publicado: (2009)

Neurofibromatosis type 2 (NF2): A clinical and molecular review
por: Evans, D Gareth R
Publicado: (2009)

Erratum: Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study
por: Carlier, A., et al.
Publicado: (2017)

Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry
por: Tabata, Mika M., et al.
Publicado: (2020)

Neurofibromatosis
por: Hovinga, Koos E., et al.
Publicado: (2020)

Impairment of Procedural Learning and Motor Intracortical Inhibition in Neurofibromatosis Type 1 Patients
por: Zimerman, Máximo, et al.
Publicado: (2015)

Antiafrodisiaco para el amor platónico /
por: Nievo, Ippolito 1831-1861
Publicado: (1995)

Increased risk of breast cancer in neurofibromatosis type 1: current insights
por: Howell, Sacha J, et al.
Publicado: (2017)

Neurofibromatosis
por: Gerber, PA, et al.
Publicado: (2009)

Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review
por: Zehou, Ouidad, et al.
Publicado: (2013)

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
por: Merker, Vanessa L., et al.
Publicado: (2018)

Are neurofibromatosis type 1 (NF1) patients at increased risk of meningioma and in particular malignant meningioma?
por: Evans, D. Gareth R., et al.
Publicado: (2022)

Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2
por: Stivaros, Stavros M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ddrdn5jhsshlf7u88m509s95s4